Overview

Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Nilotinib vs imatinib in patients with newly diagnosed CML-CP
Phase:
Early Phase 1
Details
Lead Sponsor:
Assiut University
Treatments:
Imatinib Mesylate